Skip to main content
Erschienen in: Clinical & Experimental Metastasis 4/2015

01.04.2015 | Research Paper

Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis

verfasst von: D. Subirá, M. Simó, J. Illán, C. Serrano, S. Castañón, R. Gonzalo, J. J. Granizo, M. Martínez-García, M. Navarro, J. Pardo, J. Bruna

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Some patients with epithelial-cell cancers develop leptomeningeal carcinomatosis (LC), a severe complication difficult to diagnose and with an adverse prognosis. This study explores the contribution of flow cytometry immunophenotyping (FCI) to the diagnosis and prognosis of LC. Cerebrospinal fluid (CSF) samples from patients diagnosed with LC were studied using FCI. Expression of the epithelial-cell adhesion molecule (EpCAM) was the criterion used to identify the epithelial cells. To test the diagnostic precision, 144 patients (94 diagnosed with LC) were included. The prognostic value of FCI was evaluated in 72 patients diagnosed with LC and eligible for therapy. Compared with cytology, FCI showed greater sensitivity and negative predictive value (79.79 vs. 50 %; 68.85 vs. 51.55 %, respectively), but lower specificity and positive predictive value (84 vs. 100 %; 90.36 vs. 100 %, respectively). The multivariate analysis revealed that the percentage of CSF EpCAM+ cells predicted an increased risk of death (HR: 1.012, 95 % CI 1.000–1.023; p = 0.041). A cut-off value of 8 % EpCAM+ cells in the CSF distinguished two groups of patients with statistically significant differences in overall survival (OS) (p = 0.018). This cut-off value kept its statistical significance regardless of the absolute CSF cell-count. The FCI study of the CSF improved the sensitivity for diagnosing LC, but refinement of the technique is needed to improve specificity. Furthermore, quantification of CSF EpCAM+ cells was revealed to be an independent prognostic factor for OS in patients with LC eligible for therapy. An 8 % cut-off value contributed to predicting clinical evolution before initiation of therapy.
Literatur
3.
Zurück zum Zitat Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Vrionis FD, Wen PY, National Comprehensive Cancer Network (2011) Central nervous system cancers. J Natl Compr Cancer Netw 9:352–400 Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Vrionis FD, Wen PY, National Comprehensive Cancer Network (2011) Central nervous system cancers. J Natl Compr Cancer Netw 9:352–400
4.
Zurück zum Zitat Bruna J, Simó M, Velasco R (2012) Leptomeningeal metastases. Curr Treat Options Neurol 14:402–415CrossRefPubMed Bruna J, Simó M, Velasco R (2012) Leptomeningeal metastases. Curr Treat Options Neurol 14:402–415CrossRefPubMed
5.
Zurück zum Zitat Strik H, Prömmel P (2010) Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther 10:1137–1148CrossRefPubMed Strik H, Prömmel P (2010) Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther 10:1137–1148CrossRefPubMed
6.
Zurück zum Zitat Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94:229–234CrossRefPubMed Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94:229–234CrossRefPubMed
7.
Zurück zum Zitat Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M (2004) Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91:219–224PubMedCentralPubMed Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M (2004) Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91:219–224PubMedCentralPubMed
8.
Zurück zum Zitat Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496–502CrossRefPubMed Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496–502CrossRefPubMed
9.
Zurück zum Zitat Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF (2005) Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin’s lymphoma in AIDS patients. HIV Med 6:21–26CrossRefPubMed Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF (2005) Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin’s lymphoma in AIDS patients. HIV Med 6:21–26CrossRefPubMed
10.
Zurück zum Zitat Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM, Linfomi Fondazione Italiana (2012) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 120:3222–3228. doi:10.1182/blood-2012-04-423095 Epub 2012 Aug 27CrossRefPubMed Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM, Linfomi Fondazione Italiana (2012) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 120:3222–3228. doi:10.​1182/​blood-2012-04-423095 Epub 2012 Aug 27CrossRefPubMed
11.
Zurück zum Zitat Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM, Spanish Group for the Study of CNS Disease in NHL (2010) Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 85:321–328. doi:10.1111/j.1600-0609.2010.01478.x Epub 2010 Jul 28CrossRefPubMed Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM, Spanish Group for the Study of CNS Disease in NHL (2010) Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 85:321–328. doi:10.​1111/​j.​1600-0609.​2010.​01478.​x Epub 2010 Jul 28CrossRefPubMed
12.
Zurück zum Zitat Alvarez R, Dupuis J, Plonquet A, Christov C, Copie-Bergman C, Hemery F, Gaillard I, El Gnaoui T, Kuhnowski F, Bedoui M, Belhadj K, Brugières P, Haioun C (2012) Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol 23:1274–1279CrossRefPubMed Alvarez R, Dupuis J, Plonquet A, Christov C, Copie-Bergman C, Hemery F, Gaillard I, El Gnaoui T, Kuhnowski F, Bedoui M, Belhadj K, Brugières P, Haioun C (2012) Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol 23:1274–1279CrossRefPubMed
13.
Zurück zum Zitat Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A (2014) Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 99:1228–1235CrossRefPubMedCentralPubMed Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A (2014) Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 99:1228–1235CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Subirá D, Serrano C, Castañón S, Gonzalo R, Illán J, Pardo J, Martínez-García M, Millastre E, Aparisi F, Navarro M, Dómine M, Gil-Bazo I, Pérez Segura P, Gil M, Bruna J (2012) Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. NeuroOncol 14:43–52 Subirá D, Serrano C, Castañón S, Gonzalo R, Illán J, Pardo J, Martínez-García M, Millastre E, Aparisi F, Navarro M, Dómine M, Gil-Bazo I, Pérez Segura P, Gil M, Bruna J (2012) Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. NeuroOncol 14:43–52
15.
Zurück zum Zitat de Jongste AH, Kraan J, Broek PD, Brooimans RA, Bromberg JE, Montfort KA, Smitt PA, Gratama JW (2014) Use of TransFix™ cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18 hours of storage. Cytom B Clin Cytom 86:272–279CrossRef de Jongste AH, Kraan J, Broek PD, Brooimans RA, Bromberg JE, Montfort KA, Smitt PA, Gratama JW (2014) Use of TransFix™ cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18 hours of storage. Cytom B Clin Cytom 86:272–279CrossRef
16.
Zurück zum Zitat Subirá D, Castañón S, Aceituno E, Hernández J, Jiménez-Garófano C, Jiménez A, Jiménez AM, Román A, Orfao A (2002) Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol 117:952–958CrossRefPubMed Subirá D, Castañón S, Aceituno E, Hernández J, Jiménez-Garófano C, Jiménez A, Jiménez AM, Román A, Orfao A (2002) Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol 117:952–958CrossRefPubMed
17.
Zurück zum Zitat Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A (2009) Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381–389. doi:10.1002/cncr.24041 CrossRefPubMed Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A (2009) Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381–389. doi:10.​1002/​cncr.​24041 CrossRefPubMed
18.
Zurück zum Zitat Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375CrossRefPubMed Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375CrossRefPubMed
19.
Zurück zum Zitat Chang A, Benda PM, Wood BL, Kussick SJ (2003) Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry. Am J Clin Pathol 119:643–655CrossRefPubMed Chang A, Benda PM, Wood BL, Kussick SJ (2003) Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry. Am J Clin Pathol 119:643–655CrossRefPubMed
20.
21.
Zurück zum Zitat Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007) Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. Diagn Cytopathol 35:568–578CrossRefPubMed Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007) Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. Diagn Cytopathol 35:568–578CrossRefPubMed
22.
Zurück zum Zitat Kentrou NA, Tsagarakis NJ, Tzanetou K, Damala M, Papadimitriou KA, Skoumi D, Stratigaki A, Anagnostopoulos NI, Malamou-Lada E, Athanassiadou P, Paterakis G (2011) An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions. Cytom B Clin Cytom 80:324–334. doi:10.1002/cyto.b.20608 Epub 2011 Jun 21CrossRef Kentrou NA, Tsagarakis NJ, Tzanetou K, Damala M, Papadimitriou KA, Skoumi D, Stratigaki A, Anagnostopoulos NI, Malamou-Lada E, Athanassiadou P, Paterakis G (2011) An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions. Cytom B Clin Cytom 80:324–334. doi:10.​1002/​cyto.​b.​20608 Epub 2011 Jun 21CrossRef
23.
Zurück zum Zitat Krishan A, Ganjei-Azar P, Hamelik R, Sharma D, Reis I, Nadji M (2010) Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytom A 77:132–143. doi:10.1002/cyto.a.20824 Krishan A, Ganjei-Azar P, Hamelik R, Sharma D, Reis I, Nadji M (2010) Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytom A 77:132–143. doi:10.​1002/​cyto.​a.​20824
25.
Zurück zum Zitat Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS (2011) Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2:752–760PubMedCentralPubMed Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS (2011) Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2:752–760PubMedCentralPubMed
27.
Zurück zum Zitat Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH (2005) Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92:1767–1772CrossRefPubMedCentralPubMed Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH (2005) Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92:1767–1772CrossRefPubMedCentralPubMed
29.
Zurück zum Zitat Chamberlain MC, Johnston SK, Glantz MJ (2009) Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 66:74–78CrossRefPubMed Chamberlain MC, Johnston SK, Glantz MJ (2009) Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 66:74–78CrossRefPubMed
30.
Zurück zum Zitat Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136:1729–1735. doi:10.1007/s00432-010-0831-x Epub 2010 Mar 4CrossRefPubMed Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136:1729–1735. doi:10.​1007/​s00432-010-0831-x Epub 2010 Mar 4CrossRefPubMed
31.
Zurück zum Zitat de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol 104:565–572. doi:10.1007/s11060-010-0524-y Epub 2011 Jan 14CrossRefPubMed de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol 104:565–572. doi:10.​1007/​s11060-010-0524-y Epub 2011 Jan 14CrossRefPubMed
32.
Zurück zum Zitat Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187CrossRefPubMed Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187CrossRefPubMed
34.
Zurück zum Zitat Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A, Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma (2014) Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood 123:1864–1869. doi:10.1182/blood-2013-11-537993 Epub 2014 Feb 5CrossRefPubMed Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A, Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma (2014) Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood 123:1864–1869. doi:10.​1182/​blood-2013-11-537993 Epub 2014 Feb 5CrossRefPubMed
35.
Zurück zum Zitat Illán J, Simo M, Serrano C, Castañón S, Gonzalo R, Martínez-García M, Pardo J, Gómez L, Navarro M, Pérez Altozano J, Álvarez R, Bruna J, Subirá D (2014) Differences in the cerebrospinal fluid inflammatory cell reaction of patients with leptomeningeal involvement by lymphoma and carcinoma. Transl Res 164:460–467. doi:10.1016/j.trsl.2014.03.012 CrossRefPubMed Illán J, Simo M, Serrano C, Castañón S, Gonzalo R, Martínez-García M, Pardo J, Gómez L, Navarro M, Pérez Altozano J, Álvarez R, Bruna J, Subirá D (2014) Differences in the cerebrospinal fluid inflammatory cell reaction of patients with leptomeningeal involvement by lymphoma and carcinoma. Transl Res 164:460–467. doi:10.​1016/​j.​trsl.​2014.​03.​012 CrossRefPubMed
Metadaten
Titel
Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis
verfasst von
D. Subirá
M. Simó
J. Illán
C. Serrano
S. Castañón
R. Gonzalo
J. J. Granizo
M. Martínez-García
M. Navarro
J. Pardo
J. Bruna
Publikationsdatum
01.04.2015
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 4/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-015-9716-3

Weitere Artikel der Ausgabe 4/2015

Clinical & Experimental Metastasis 4/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.